Xultophy 100/3.6 Flexpen Injection 100Iu (1 Box = 1 Injection)

XULTOPHY 100/3

PKR 10071.60

PKR 9568.02

You save: PKR 503.58

Quantity:

SKU: XULTOPHY_INJECTION_100UNITS_3ML_NV

Category: Temp control medicines

XULTOPHY 100/3.6 is a combination product consisting of insulin degludec and liraglutide. Insulin degludec : The primary activity of insulin degludec is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis. Liraglutide : Liraglutide is a GLP-1 receptor agonist that increases glucosedependent insulin release, decreases glucagon secretion, and slows gastric emptying .

Purpose

Diabetes Management

Ingredients

Insulin degludec + Liraglutide

Warnings

Instruct patients to check the label before each injection since accidental mix-ups with insulin containing products can occur. Avoid administer more than 50 units of Xultophy 100/3.6 daily. Avoid exceed the 1.8 mg maximum recommended dose of liraglutide or use with other GLP-1 RAs.
Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported postmarketing for liraglutide, usually in association with nausea, vomiting, diarrhea, or dehydration. Advise patients of the potential risk of dehydration due to gastrointestinal adverse reactions and take precautions to avoid fluid depletion.
All insulin containing products, including Xultophy 100/3.6 can lead to life-threatening hypokalemia, which may then cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.

Side Effects

Hypoglycaemia , nausea , diarrhoea , vomiting , constipation , dyspepsia , gastritis , abdominal pain , GERD , abdominal distension , inj-site reaction .